Eloxx Pharmaceuticals (ELOX) & Its Rivals Head-To-Head Survey

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 903 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Eloxx Pharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	1	2.75
Eloxx Pharmaceuticals Competitors	7576	13627	25428	997	2.42

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, suggesting a potential upside of 154.91%. As a group, “Pharmaceuticals” companies have a potential upside of 32.55%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Eloxx Pharmaceuticals is more favorable than its competitors.

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ competitors have a beta of -3.18, meaning that their average share price is 418% less volatile than the S&P 500.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.57
Eloxx Pharmaceuticals Competitors	$3.48 billion	$3.12 billion	543.72

Eloxx Pharmaceuticals’ competitors have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Eloxx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,309.62%	-222.80%	-17.20%

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Eloxx Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.